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Rapidly Progressing, Diffuse Violaceous Nodules as a Presenting Symptom for
Aggressive Acute Myeloid Leukemia

Lusia S. Yi, DO, MS and Arthur C. Sosis, MD
Lehigh Valley Health Network, Allentown, Pennsylvania and Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania

Case Presentation:

History of Present Illness: The patient was initially seen at our acute care
clinic in May 2010 for evaluation of diffuse lumps that started three or four weeks
prior. Patient noticed the lumps, which began on his chest and arms, after cutting
maple trees in his backyard. Over several weeks, he noticed rapid progression and
development of numerous nodules all over his body, but denied symptoms including
pain, pruritus, bleeding, or changes in color. Patient reported mild shortness of
breath, which he attributed to physical activites during that time. Review of systems
for fever, chills, night sweats, weight loss, hemoptysis, nausea, vomiting, diarrhea,
constipation, melena, or hematuria was unremarkable.
Medical History/Surgical History: Peptic ulcer disease, eczema,
allergies, urinary blockage repair
Family History: Lung cancer, prostate cancer
Medications: None
Physical Examination: There are numerous pink to violaceous subcutaneous
nodules measuring about 1-2cm on neck, arms, chest, abdomen, back, legs, and
groin (figure 1). There was no palpable cervical, supraclavicular, axillary, or inguinal
adenopathy. There was no hepatosplenomegaly.
Laboratory Data: CBC with diff (05/14/10) is WNL except elevated neutrophils
of 72% (40-70%). CMP is WNL (05/14/10). Lactate dehydrogenase (06/15/10) is
1.5mmol/L (0.5-2.1mmol/L).
Studies: CT chest (5/26/10): “large right-sided pleural effusion with mediastinal
shift…large anterior mediastinal mass with significant adenopathy concerning for
lymphoma.”
Biopsy:
CBLPath (D10NY1-0175157) 1. Left medial clavicle, 2. Left shoulder: “Dermal
infiltration by a monomorphous population of medium-sized atypical cells with blast
features partially effacing the normal architecture…positive staining of the atypical
cells for CD56, CD43, CD23, CD117, and bcl-2, in majority of them positive staining
for myeloperoxidase.” (Figure 2)
Health Network Laboratories (SM10-2582) Bone marrow aspirate smear, clot
section and core biopsy, right posterior iliac crest: “normocellular marrow with
trilineage hematopoiesis involved by an acute myeloid leukemia.”
Cytogenics by FISH revealed: negative NPMI and FLT3-ITD mutation, trisomies
5 and 7 consistent with an AML, and partial deletions of the long arms of
chromosomes 5,7, and 20.
Diagnosis: Aleukemic leukemia cutis
Disease Course: Twelve days after the initial presentation, patient developed
rapid progression of shortness breath and was admitted to the hospital with a
malignant pleural effusion. At that time, cytology of pleural effusion and bone
marrow biopsy were done and revealed the diagnosis of acute myeloid leukemia.
Patient rapidly deteriorated with multi-organ metastasis and died of fungal
pneumonia thirty-seven days after the initial presentation.

Discussion:

Figure 1:
Diffusely distributed numerous pink to violaceous subcutaneous nodules.
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Figure 2:
(A-D) H&E histopathologic findings: A(2X), B(4X), C(10X)- Diffuse dense infiltrate involving the dermis and subcutis with sparing of the
upper papillary dermis; D(40X)- At high-power magnification, large hyperchromatic cells and mitotic figures are seen.
(E-S) Immunohistochemical findings.
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Diagnostic Immunophenotypic Profile of Leukemia Cutis
ALL-acute lymphoblastic leukemia; AML-acute myeloid leukemia; AMoL-acute monocytic leukemia; AMMoL-acute myelomonocytic
leukemia; ATLL- adult-Tcell leukemia/lymphoma; CLL-chronic lymphocytic leukemia; CML-chronic myeloid leukemia; MPO-myeloperoxidase;
SS-Sezary syndrome; TdT-terminal deoxynucleotidyl transferase; T-PLL-T-cell prolymphocytic leukemia (adopted from: Cho-Vega JH,
Medeiros LJ, Prieto VG, Vega F. Leukemia Cutis. Anatomic Pathology 2008;129:130-142.)

Leukemia cutis (LC) is defined as cutaneous infiltration by malignant leukocytes of
myeloid or lymphoid lineage, resulting in clinical skin lesions. LC has been reported
in patients with acute myeloid leukemia (AML), chronic myeloproliferative disease,
including chronic myelogenous leukemia (CML), myelodysplastic syndrome, and
myelodysplatic/lymphoproliferative diseases. Overall, LC occurs in 10-15% of patients
with AML. In the majority of cases, LC presents concomitantly or after a diagnosis
of systemic leukemia has been made. Rarely, in less than 10% of cases, LC has
been reported to occur in the absence of systemic symptoms before bone marrow
or peripheral blood involvement. The term “aleukemic leukemia cutis” or “primary
extramedullary leukemia” has been used to describe this rare phenomenon, which has
been shown to occur predominately in patients with AML.
Clinically, LC can cause non-specific reactive skin lesions or present with single or
multiple lesions of violaceous, red-brown, or hemorrhagic papules, nodules, and
plaques. LC lesions present most commonly on the head, neck, and trunk. It also
favors sites of previous or existing inflammation. Aleukemic LC lesions are usually
papulonodular and diffusely distributed. Histopathologically, findings of LC vary with the
type of leukemia, but typically show diffuse infiltrate or tumor nodules of leukemic cells
in the dermis. Frequently, there are dense peri-vascular and peri-eccrine infiltrates and
lining of single cells through the interstitial collagen in the superficial and deep dermis.
More importantly, immunophenotype assessment is essential in diagnosing the specific
type of leukemia (figure 3). Furthermore, specific chromosomal abnormalities have
been shown to be associated with certain types of LC. For example, abnormalities of
chromosome 8 have been detected more frequently in LC patients with AML.
Development or presence of LC does not provide relevant epidemiologic, and or, clinical
data regarding sex, age, WBC count, hemoglobin concentration, platelet count, and
fibrinogen level. However, higher serum levels of lactate dehydrogenase and or β2microglobulin, which correlate to the negative prognostic factors, have been associated
in patients with LC than in patients without LC. In general, the development of leukemia
cutis suggests a poor prognosis. Recent study suggested that chronic myelomonocytic
leukemia in the presence of LC have significantly increased risk of transformation
to AML and intensive extramedullary involvement with shortened survival. It has
been reported that about 88% of patients with leukemia cutis die within one year of
the diagnosis. In contrast to adult leukemic patients, LC does not portend a worse
prognosis in patients with congenital leukemia.
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